Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial

BACKGROUND: The randomized, double-blind, placebo-controlled GRID trial tested the oral multikinase inhibitor regorafenib in 199 patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib, and showed a significant improvement in progression-fre...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Clin Oncol
Main Authors: Komatsu, Yoshito, Doi, Toshihiko, Sawaki, Akira, Kanda, Tatsuo, Yamada, Yasuhide, Kuss, Iris, Demetri, George D, Nishida, Toshirou
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4527951/
https://ncbi.nlm.nih.gov/pubmed/25655899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-015-0790-y
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares